FORT WORTH, Texas, May 11, 2011 /PRNewswire/ -- Healthpoint Biotherapeutics today announced the introduction of OASIS® Ultra Tri-Layer Matrix, a natural extracellular matrix (ECM) material derived from three layers of porcine small intestinal submucosa (SIS). The three-layer construct of ECM was designed to incorporate increased structure into difficult-to-heal and chronic wounds.
"We are pleased to introduce OASIS® Ultra as an extension of our SIS product offerings," said Travis Baugh, President and Chief Operating Officer of Healthpoint Biotherapeutics. "The three-layer design provides healthcare professionals with an important therapeutic option for temporary ECM replacement in complex wounds where increased strength and thickness is called for as part of the treatment protocol."
SIS, the base technology for OASIS® Ultra, is among the most widely studied and published biomaterials, featured in more than 832 scientific publications.
OASIS® Ultra is indicated for the management of wounds including surgical, partial- and full-thickness, traumatic (including second degree burns), venous ulcers, chronic vascular ulcers, diabetic and pressure ulcers, and draining wounds. The product should not be used in patients with known sensitivity to porcine material and is not indicated for use in third-degree burns.
About Healthpoint Biotherapeutics
Healthpoint Biotherapeutics is a biopharmaceutical company focused on the development and commercialization of novel, cost-effective solutions for tissue repair and healing. The company's diversified research and development strategy is presently centered around therapeutic enzymes, biologics and next-generation cell- and cell-matrix based therapies for the prevention and treatment of acute, chronic and burn-related wounds. Currently marketed products include Collagenase SANTYL® Ointment, OASIS® Wound Matrix and OASIS® Ultra Tri-Layer Matrix. Heal